↓ Skip to main content

Immunogenicity and safety of influenza vaccination in patients with juvenile idiopathic arthritis on biological therapy using the microneutralization assay

Overview of attention for article published in Pediatric Rheumatology, August 2017
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (63rd percentile)
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
5 tweeters

Citations

dimensions_citation
19 Dimensions

Readers on

mendeley
42 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Immunogenicity and safety of influenza vaccination in patients with juvenile idiopathic arthritis on biological therapy using the microneutralization assay
Published in
Pediatric Rheumatology, August 2017
DOI 10.1186/s12969-017-0190-0
Pubmed ID
Authors

M. S. Camacho-Lovillo, A. Bulnes-Ramos, W. Goycochea-Valdivia, L. Fernández-Silveira, E. Núñez-Cuadros, O. Neth, P. Pérez-Romero

Abstract

Seasonal influenza virus vaccination should be considered in all pediatric patients with rheumatic diseases. Few studies have addressed influenza vaccination safety and efficacy in this group. We aim to prospectively evaluate immunogenicity and safety of the trivalent inactivated influenza vaccine including A/H1N1, A/H3N2 and B strains in children with juvenile idiopathic arthritis (JIA) receiving biological therapy. Thirty-five children diagnosed with JIA and 6 healthy siblings were included. Serum samples were collected prior to, 4-8 weeks and one year after vaccination. Microneutralization assays were used to determine neutralizing antibody titers. The type and duration of therapy were analyzed to determine its effect on vaccine response. Clinical data of the participants were collected throughout the study including severe adverse events (SAE) and adverse events following immunization (AEFI). Twenty-five patients (74.3%) received biological treatment for JIA; anti TNF-α was prescribed in 15, anti IL-1 receptor in 4 and anti IL-6 receptor therapy in 6 children. The seroprotection rate 4-8 weeks after vaccination in the JIA group was 96% for influenza A/(H1N1)pdm and influenza A/H3N2, and 88% for influenza B. No differences were found in GMT, seroprotection and seroconversion rates for the three influenza strains between the control group and patients receiving biological therapy. Furthermore, long-term seroprotection at 12 months after vaccination was similar in patients receiving either biological or non-biological treatments. No SAEs were observed. In this study, influenza vaccination was safe and immunogenic in children with JIA receiving biological therapy.

Twitter Demographics

The data shown below were collected from the profiles of 5 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 42 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 42 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 8 19%
Student > Ph. D. Student 4 10%
Researcher 4 10%
Student > Master 4 10%
Other 3 7%
Other 9 21%
Unknown 10 24%
Readers by discipline Count As %
Medicine and Dentistry 11 26%
Pharmacology, Toxicology and Pharmaceutical Science 4 10%
Nursing and Health Professions 4 10%
Biochemistry, Genetics and Molecular Biology 2 5%
Veterinary Science and Veterinary Medicine 2 5%
Other 6 14%
Unknown 13 31%

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 31 August 2017.
All research outputs
#3,292,971
of 11,682,907 outputs
Outputs from Pediatric Rheumatology
#88
of 317 outputs
Outputs of similar age
#92,893
of 266,962 outputs
Outputs of similar age from Pediatric Rheumatology
#6
of 9 outputs
Altmetric has tracked 11,682,907 research outputs across all sources so far. This one is in the 49th percentile – i.e., 49% of other outputs scored the same or lower than it.
So far Altmetric has tracked 317 research outputs from this source. They receive a mean Attention Score of 3.7. This one has gotten more attention than average, scoring higher than 68% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 266,962 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 63% of its contemporaries.
We're also able to compare this research output to 9 others from the same source and published within six weeks on either side of this one. This one has scored higher than 3 of them.